FBRX
Forte Biosciences, Inc.
Biotechnology
Market Cap$76M
5Y Perf.-94.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
FBRX vs SLDB
Revenue, margins, valuation, and 5-year total return — side by side.
SLDB
Solid Biosciences Inc.
Biotechnology
Market Cap$551M
5Y Perf.-83.6%
FBRX vs SLDB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | FBRX | SLDB |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $76M | $551M |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-52M | $-167M |
| Total Debt | $0.00 | $21M |
| Cash & Equiv. | $22M | $60M |
FBRX vs SLDB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
FBRX
SLDB
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Forte Biosciences, … (FBRX) | 100 | 5.3 | -94.7% |
| Solid Biosciences I… (SLDB) | 100 | 16.4 | -83.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: FBRX vs SLDB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FBRX leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
FBRX
Forte Biosciences, Inc.
The Income Pick
FBRX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.57
- EPS growth 51.2%
- Lower volatility, beta 1.57, current ratio 6.76x
Best for: income & stability and growth exposure
SLDB
Solid Biosciences Inc.
The Long-Run Compounder
SLDB is the clearest fit if your priority is long-term compounding.
- -97.9% 10Y total return vs FBRX's -99.4%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FBRX | -51.3% revenue growth vs SLDB's -65.1% |
| Stability / Safety | FBRX | Beta 1.57 vs SLDB's 2.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FBRX | +322.8% vs SLDB's +173.0% |
| Efficiency (ROA) | FBRX | -53.3% ROA vs SLDB's -60.0%, ROIC -102.5% vs -120.8% |
FBRX vs SLDB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLFBRXLAGGINGSLDB
SLDBSolid Biosciences Inc.
1leads
FBRXForte Biosciences, In…
2leads
6 Total Categories
CATEGORYLEADERvs SLDBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
FBRX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
FBRX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
SLDB5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
FBRX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
FBRX and SLDB operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | FBRXForte Biosciences… | SLDBSolid Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$53M | -$168M |
| Net IncomeAfter-tax profit | -$52M | -$167M |
| Free Cash FlowCash after capex | -$45M | -$133M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +78.2% | +39.2% |
FBRX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — FBRX and SLDB each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | FBRXForte Biosciences… | SLDBSolid Biosciences… |
|---|---|---|
| Market CapShares × price | $76M | $551M |
| Enterprise ValueMkt cap + debt − cash | $54M | $512M |
| Trailing P/EPrice ÷ TTM EPS | -2.15x | -3.55x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.45x | 3.44x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — FBRX and SLDB each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
FBRX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
FBRX delivers a -61.5% return on equity — every $100 of shareholder capital generates $-62 in annual profit, vs $-74 for SLDB. On the Piotroski fundamental quality scale (0–9), SLDB scores 3/9 vs FBRX's 2/9, reflecting mixed financial health.
| Metric | FBRXForte Biosciences… | SLDBSolid Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | -61.5% | -73.6% |
| ROA (TTM)Return on assets | -53.3% | -60.0% |
| ROICReturn on invested capital | -102.5% | -120.8% |
| ROCEReturn on capital employed | -83.4% | -100.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | — | 0.12x |
| Net DebtTotal debt minus cash | -$22M | -$39M |
| Cash & Equiv.Liquid assets | $22M | $60M |
| Total DebtShort + long-term debt | $0 | $21M |
| Interest CoverageEBIT ÷ Interest expense | — | -822.33x |
FBRX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
SLDB leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SLDB five years ago would be worth $999 today (with dividends reinvested), compared to $321 for FBRX. Over the past 12 months, FBRX leads with a +322.8% total return vs SLDB's +173.0%. The 3-year compound annual growth rate (CAGR) favors SLDB at 9.3% vs FBRX's -0.4% — a key indicator of consistent wealth creation.
| Metric | FBRXForte Biosciences… | SLDBSolid Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | +10.8% | +29.7% |
| 1-Year ReturnPast 12 months | +322.8% | +173.0% |
| 3-Year ReturnCumulative with dividends | -1.2% | +30.7% |
| 5-Year ReturnCumulative with dividends | -96.8% | -90.0% |
| 10-Year ReturnCumulative with dividends | -99.4% | -97.9% |
| CAGR (3Y)Annualised 3-year return | -0.4% | +9.3% |
SLDB leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — FBRX and SLDB each lead in 1 of 2 comparable metrics.
Risk & Volatility
FBRX is the less volatile stock with a 1.57 beta — it tends to amplify market swings less than SLDB's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SLDB currently trades 79.7% from its 52-week high vs FBRX's 73.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | FBRXForte Biosciences… | SLDBSolid Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.47x | 2.18x |
| 52-Week HighHighest price in past year | $35.80 | $8.87 |
| 52-Week LowLowest price in past year | $6.13 | $2.41 |
| % of 52W HighCurrent price vs 52-week peak | +73.1% | +79.7% |
| RSI (14)Momentum oscillator 0–100 | 44.0 | 44.7 |
| Avg Volume (50D)Average daily shares traded | 273K | 1.3M |
Evenly matched — FBRX and SLDB each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates FBRX as "Buy" and SLDB as "Buy". Consensus price targets imply 148.4% upside for FBRX (target: $65) vs 126.3% for SLDB (target: $16).
| Metric | FBRXForte Biosciences… | SLDBSolid Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $65.00 | $16.00 |
| # AnalystsCovering analysts | 6 | 21 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
FBRX leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SLDB leads in 1 (Total Returns). 2 tied.
Best OverallForte Biosciences, Inc. (FBRX)Leads 2 of 6 categories
Loading custom metrics...
FBRX vs SLDB: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is FBRX or SLDB a better buy right now?
Analysts rate Forte Biosciences, Inc.
(FBRX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — FBRX or SLDB?
Over the past 5 years, Solid Biosciences Inc.
(SLDB) delivered a total return of -90. 0%, compared to -96. 8% for Forte Biosciences, Inc. (FBRX). Over 10 years, the gap is even starker: SLDB returned -97. 9% versus FBRX's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — FBRX or SLDB?
By beta (market sensitivity over 5 years), Forte Biosciences, Inc.
(FBRX) is the lower-risk stock at 1. 47β versus Solid Biosciences Inc. 's 2. 18β — meaning SLDB is approximately 48% more volatile than FBRX relative to the S&P 500.
04Which is growing faster — FBRX or SLDB?
On earnings-per-share growth, the picture is similar: Forte Biosciences, Inc.
grew EPS 51. 2% year-over-year, compared to 35. 0% for Solid Biosciences Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — FBRX or SLDB?
Forte Biosciences, Inc.
(FBRX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Solid Biosciences Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: FBRX leads at 0. 0% versus 0. 0% for SLDB. At the gross margin level — before operating expenses — FBRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — FBRX or SLDB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is FBRX or SLDB better for a retirement portfolio?
For long-horizon retirement investors, Forte Biosciences, Inc.
(FBRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Solid Biosciences Inc. (SLDB) carries a higher beta of 2. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (FBRX: -99. 5%, SLDB: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between FBRX and SLDB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.